高级检索
当前位置: 首页 > 详情页

Down-regulated microRNA-195-5p and up-regulated CXCR4 attenuates the heart function injury of heart failure mice via inactivating JAK/STAT pathway.

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [a]Department of Cardiology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518106, Guangdong, China [b]Nanhai Hospital, Southern Medical University Carvascular Medicine, Foshan 528244, Guangdong, China
出处:
ISSN:

关键词: Heart failure MicroRNA-195-5p CXCR4 JAK/STAT pathway Heart function Cardiomyocyte

摘要:
Little is known regarding the functional role of microRNA-195-5p (miR-195-5p) in heart failure (HF). Hence, the aim of the present study was to investigate the effect of miR-195-5p on cardiac function in mice with HF and its mechanism through the regulation of Chemokine receptor type 4 (CXCR4) and Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway. The mice model of HF was established by transverse aortic constriction, the successfully modeled mice were injected with anti-miR-195-5p and OE-CXCR4. The expression of miR-195-5p, CXCR4, JAK2 and STAT1 in the myocardial tissues of each group were detected. The target relationship between miR-195-5p and CXCR4 was verified. The indices of cardiac ultrasound, hemodynamics, oxidative stress, inflammatory factor, myocardial enzyme and cardiac function were detected. MiR-195-5p, JAK2 and STAT1 expression were raised and CXCR4 expression was degraded in myocardial tissues of HF mice and CXCR4 was the target gene of miR-195-5p. Down-regulated miR-195-5p and up-regulated CXCR4 ameliorated cardiac function, abated inflammatory factors contents, oxidative stress reaction and myocardial enzyme indices in HF mice. Down-regulated miR-195-5p and up-regulated CXCR4 suppressed apoptosis of cardiomyocytes in HF mice. Depleting miR-195-5p and up-regulating CXCR4 alleviates cardiac function injury in mice with HF via inhibition of JAK/STAT signaling pathway activation. MiR-195-5p might be a potential candidate marker and therapeutic target for HF. Copyright © 2020. Published by Elsevier B.V.

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 3 区 医学
小类 | 3 区 免疫学 3 区 药学
最新[2025]版:
大类 | 2 区 医学
小类 | 2 区 药学 3 区 免疫学
JCR分区:
出版当年[2018]版:
Q2 IMMUNOLOGY Q2 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q1 PHARMACOLOGY & PHARMACY Q2 IMMUNOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [a]Department of Cardiology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen 518106, Guangdong, China
通讯作者:
通讯机构: [b]Nanhai Hospital, Southern Medical University Carvascular Medicine, Foshan 528244, Guangdong, China [*1]Nanhai Hospital, Southern Medical University Carvascular Medicine, 28 Liguan Road, Lishui Town, Nanhai District, Foshan 528244, Guangdong, China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2021 今日访问量:0 总访问量:646 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号